FDA
-
-
-
-
-
-
-
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy
-
-
-
-
-
-
-
AVROBIO Inc. (AVRO) Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
-
-
-
-
-
-
-
AVROBIO Inc. (AVRO) Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
-
-
-
-
-
-
-
Avrobio Inc. (AVRO) PT Lowered to $6 at Mizuho Securities
-
-
-
-
-
-
-
AVROBIO Inc. (AVRO) Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease
-
-
-
-
-
-
-
AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline
-
-
-
-
-
-
-
AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
-
251,639 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All